Erlotinib and gefitinib are first-generation EGFR-TKIs with non-covalent and reversible binding activity to receptor tyrosine kinase and are both approved treatments for patients of advanced NSCLC harboring sensitizing EGFR mutation1,2. This evidence concerns the gene EGFR and non-small cell lung carcinoma.